Myelofibrosis (MF) Global Market Report 2025

The myelofibrosis (MF) market size has grown steadily in recent years. It will grow from $1.5 billion in 2024 to $1.55 billion in 2025 at a compound annual growth rate (CAGR) of 3.5%. The growth during the historic period can be attributed to factors such as the rising prevalence of myeloproliferative neoplasms, greater awareness and earlier diagnosis, the growing adoption of JAK inhibitors, improved access to bone marrow transplants, and more regulatory approvals for new therapies.

The myelofibrosis (MF) market size is expected to see steady growth in the next few years. It will grow to $1.76 billion in 2029 at a compound annual growth rate (CAGR) of 3.2%. The growth during the forecast period can be attributed to factors such as the rising demand for personalized treatment approaches, an increase in clinical trials for gene and cell therapies, a growing use of combination therapies, expanding healthcare coverage for rare diseases, and increased investment in hematology care. Key trends expected in this period include advancements in gene-editing technologies, innovations in fibrosis-targeting drugs, the development of next-generation JAK inhibitors, growing interest in immunotherapy for myelofibrosis, and the expanding use of artificial intelligence in drug discovery.

The growing demand for targeted therapies is expected to drive the growth of the myelofibrosis (MF) market. Targeted therapies are an approach that tailors treatments and healthcare decisions based on an individual’s genetic, environmental, and lifestyle factors. The increasing demand for these therapies is fueled by advancements in genomics, biotechnology, and data analytics, which allow for more precise, effective, and personalized treatments. Myelofibrosis serves as a key example in the development of targeted therapies by highlighting critical molecular pathways, such as JAK-STAT signaling. These pathways enable the design of precision treatments such as JAK inhibitors (Ruxolitinib, Fedratinib, and Pacritinib) that help manage symptoms and slow the progression of the disease. For instance, in April 2024, the American Society of Gene & Cell Therapy reported that the number of therapies in clinical development has grown, with Phase I therapies showing the most significant increase, rising by 11% - the highest growth rate since Q4 2022. As a result, the growing demand for targeted therapies is expected to continue driving growth in the myelofibrosis market.

Companies in the myelofibrosis market are focusing on expanding targeted therapies to enhance treatment efficacy, address disease progression, and improve patient outcomes. JAK1/JAK2 inhibitors, for example, target the Janus kinase pathway to reduce inflammation and abnormal blood cell production in myelofibrosis, while ACVR1 inhibitors block activin receptor-like kinase 2 (ALK2) to regulate bone marrow fibrosis and disease progression. A notable example is in September 2023 when GSK plc, a UK-based pharmaceutical company, received approval from the U.S. Food and Drug Administration (FDA) for Ojjaara (momelotinib). This treatment, designed for patients with intermediate- or high-risk myelofibrosis, has a dual mechanism of action that targets both JAK1/JAK2 and ACVR1. It helps regulate inflammatory pathways and improves hemoglobin levels, reducing the need for transfusions. This approval expands treatment options and sets a new standard in the management of MF, particularly for patients struggling with anemia, a significant unmet need in the disease landscape.

In February 2024, Novartis AG, a Swiss pharmaceutical company, acquired MorphoSys AG for EUR 2.7 billion ($2.91 billion). The acquisition enables Novartis to gain full ownership of pelabresib (CPI-0610), a promising treatment for myelofibrosis when combined with ruxolitinib, and tulmimetostat (CPI-0209), an investigational dual EZH1/EZH2 inhibitor being evaluated for solid tumors and lymphomas. This acquisition strengthens Novartis' oncology pipeline by adding innovative therapies aimed at addressing critical unmet medical needs in the field of oncology and myelofibrosis.

Major players in the myelofibrosis (MF) market are Pfizer Inc., F. Hoffmann-La Roche Ltd., Merck & Co. Inc., AbbVie Inc., Sanofi S.A., Bristol-Myers Squibb Company, Novartis AG, GlaxoSmithKline plc, Eli Lilly and Company, Gilead Sciences Inc., A. Menarini Industrie Farmaceutiche Riunite S.r.l., Incyte Corporation, Sobi Inc., MorphoSys AG, CTI BioPharma Corp., Suzhou Zelgen Biopharmaceutical Co. Ltd., NS Pharma Inc., Impact Biomedicines Inc., Kartos Therapeutics Inc., Geron Corporation.

North America was the largest region in the myelofibrosis (MF) market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in myelofibrosis (MF) report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the myelofibrosis (MF) market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Myelofibrosis (MF) is a rare bone marrow disorder marked by the excessive formation of scar tissue, which impairs the normal production of blood cells. This condition can cause anemia, an enlarged spleen, and symptoms such as fatigue, night sweats, and bone pain.

The primary drug types used for treating myelofibrosis include JAK inhibitors, immunomodulators, hydroxyurea, and other therapies. JAK inhibitors are medications that block Janus kinase enzymes, which are involved in signaling pathways responsible for inflammation, immune response, and cell growth. These inhibitors are commonly used to treat conditions such as rheumatoid arthritis and myelofibrosis. Treatment options for MF include chemotherapy, targeted therapy, and other types of treatment. The medications can be administered orally, parenterally, or through other routes. They are distributed via hospital pharmacies, online pharmacies, and retail pharmacies, with key end users including hospitals, home care settings, specialty clinics, and other healthcare facilities.

The myelofibrosis (MF) market research report is one of a series of new reports that provides myelofibrosis (MF) market statistics, including the myelofibrosis (MF) industry global market size, regional shares, competitors with the myelofibrosis (MF) market share, detailed myelofibrosis (MF) market segments, market trends, and opportunities, and any further data you may need to thrive in the myelofibrosis (MF) industry. This myelofibrosis (MF) market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The myelofibrosis (MF) market consists of revenues earned by entities by providing services such as diagnostic services, patient support programs, and clinical trials. The market value includes the value of related goods sold by the service provider or included within the service offering. The myelofibrosis (MF) market also includes sales of hematological diagnostic tools, novel fibrosis-targeting drugs, and evolving regenerative therapies. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values generated by organizations in the specified geography within the market, irrespective of where they are produced. They do not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.